Xilio Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
828 Winter St Ste 300, Waltham, Massachu...Phone Number
(857) 524-2466Website
www.xiliotx.comRevenue
$64.1 MillionStock Symbol
XLOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Xilio Therapeutics
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Xilio Therapeutics was established in 2016, and is headquartered in Massachusetts, United States.Explore more
Xilio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xilio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Xilio Therapeutics had a recent Job posting/layoffs
Xilio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Xilio Therapeutics recently announced quarterly report
Product Launch: Get notified when Xilio Therapeutics launches new products
Check if Xilio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Xilio Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Xilio Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Xilio Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Xilio Therapeutics
Compare insights from companies similar to Xilio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xilio Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Xilio Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Xilio Therapeutics.
Xilio Therapeutics financials insights
Gather financial insights about Xilio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$7.5M
2018
Series A
$30M
2020
Series B
$100.5M
2021
Series C
$95M
Stock Offering
$118M
2024
Share Placement
$11.3M
Xilio Therapeutics Tech Stack
A closer look at the technologies used by Xilio Therapeutics
Most Recent Scoops
Open Position
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Person-Based
Xilio Therapeutics News & Media
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xilio Therapeutics
Sign Up For FreeTo access detailed company insights
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Xilio Therapeutics was established in 2016, and is headquartered in Massachusetts, United States.... Read More
